💬
🤖
AI Support
24/7 online · instant AI reply
✕
📡 24/7 Live Updates

News Square

Global Crypto News · Real-time Aggregation

Fear & Greed
65
Greed (+3)
BTC $72,134 +2.3%
ETH $3,892 +1.8%
SOL $168 +4.2%
13h ago · Decrypt

OpenAI Buys Orchestra Bio to Put AI Agents in Charge of Drug Development Grunt Work

OpenAI has bought Orchestra Bio, a San Francisco startup whose AI agents help drug companies keep sprawling development programs on schedule, the ChatGPT maker <a href="https://openai.com/index/openai-to-acquire-orchestra-bio/" target="_blank" rel="nofollow external noopener" class="sc-adb616fe-0 dJryYS">>announced Tuesday</a>. “Our goal is to help scientists make discoveries and manage the work needed to turn them into treatments that reach patients sooner,” OpenAI said in the announcement. Orchestra’s team and platform will be folded into <a href="https://openai.com/rosalind/" target="_blank" rel="nofollow external noopener" class="sc-adb616fe-0 dJryYS">>Rosalind</a>, OpenAI’s family of AI models and tools for biologists and chemists. The financial terms were not disclosed. Getting a new medicine from first idea to U.S. approval takes time—up to 15 years according to OpenAI. Every month shaved off that timeline is a month earlier that a new treatment can reach the people waiting for it, and a month earlier that the company can generate cash. The process is also absurdly expensive: bringing one approved drug to market can cost more than <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12668846/" target="_blank" rel="nofollow external noopener" class="sc-adb616fe-0 dJryYS">>$2.6 billion</a>, and <a href="https://arxiv.org/pdf/2106.05386" target="_blank" class="sc-adb616fe-0 dJryYS" rel="nofollow">fewer than 10%</a> of candidates that enter human testing ever make it to pharmacy shelves. Beyond the science itself, OpenAI says drug teams have to coordinate work across internal departments and outside partners, often relying on systems that don’t talk to each other. Those partners usually include contract research organizations, the outside labs hired to run studies, and contract manufacturers that produce the experimental drug. Orchestra’s AI agents—software that can watch over tasks and flag problems on its own—work out which activities and deadlines take the hit, gather the relevant information and compare ways to respond, while scientists and program leaders make the final call. Founded in the fall of 2022, Orchestra raised its <a href="https://jobs.8vc.com/companies/orchestra/jobs/28818089-senior-software-engineer" target="_blank" rel="nofollow external noopener" class="sc-adb616fe-0 dJryYS">>seed round</a> from Andreessen Horowitz, Definition Capital, Insight Partners, and 8VC, and about $20 million in total, according to <a href="https://www.caplight.com/company/orchestra-bio" target="_blank" class="sc-adb616fe-0 dJryYS" rel="nofollow">Caplight data</a>. The company should not be confused with Orchestra BioMed, an unrelated Nasdaq-listed medical device maker that trades under the ticker OBIO. In April, OpenAI launched <a href="https://decrypt.co/364783/openai-gpt-rosalind-drug-discovery-life-sciences-model" target="_blank" class="sc-adb616fe-0 dJryYS" rel="nofollow">GPT-Rosalind</a>, a model built specifically for biology and dru

→
Flash 2026-10-21 19:43:10 · Bijing Flash

The U.S. OCC finalizes the GENIUS Act rules, abandoning restrictions on stablecoin rewards.

CoinWorld news: The U.S. Office of the Comptroller of the Currency (OCC) has finalized the GENIUS Act rules, abandoning restrictions on stablecoin rewards. This decision leaves the main dispute between banks and crypto companies unresolved.

→
Flash 2026-10-21 19:42:31 · Bijing Flash

Coinbase宣布已在官网及App上线Axis Robotics(AXIS)

Coinbase has announced that Axis Robotics (AXIS) is now available on the Coinbase website and app. Users can buy, sell, convert, send, receive, and store the asset through the platform, with specific service availability varying by jurisdiction.

→
Flash 2026-10-21 19:40:32 · Bijing Flash

The first stablecoin rules under the GENIUS Act signed by Trump have been issued.

According to CoinWorld news, before the GENIUS Act signed by Trump takes effect in January 2027, the first final rules on stablecoins have been issued. The U.S. Office of the Comptroller of the Currency (OCC) has relaxed its regulation of stablecoin rewards, removing language stating that certain third-party arrangements are illegal. These rewards will be subject to case-by-case review, while issuers remain prohibited from paying interest directly. The OCC is the first federal banking regulator to finalize rules under the law.

→
Flash 2026-10-21 19:40:03 · Bijing Flash

Samsung Electro-Mechanics signs multi-year supply agreement with Nvidia

CoinWorld news: Samsung Electro-Mechanics has signed a binding multi-year supply agreement with Nvidia to provide ABF packaging substrates for AI processors and high-speed network switches, with deliveries beginning in 2026.

→
Flash 2026-10-21 19:37:37 · Bijing Flash

Former Google CEO Eric Schmidt invested in Anthropic for about a 1% stake.

Coin World news, according to a Benzinga report, former Google CEO Eric Schmidt invested tens of millions of dollars in its Series A funding round and reportedly holds about a 1% stake in Anthropic. At a valuation of $2 trillion, that stake would be worth approximately $20 billion.

→
Flash 2026-10-21 19:34:56 · Bijing Flash

Amkor and Nvidia reach an agreement totaling $3 billion.

CoinWorld news: Amkor has added a $1.3 billion Nvidia agreement, bringing its multi-year total with Nvidia to $3 billion.

→
Flash 2026-10-21 19:34:27 · Bijing Flash

CrowdStrike与Nvidia扩展AI安全技术

CrowdStrike and Nvidia have announced that they will extend AI agent security technology from software to silicon chips, aiming to enhance cybersecurity protection capabilities.

→
Flash 2026-10-21 19:34:05 · Bijing Flash

German company TÜV SÜD, together with Accenture and NVIDIA, is advancing safety certification for physical AI, and production facilities are expected to be operational up to 30% earlier.

CoinWorld news, Cailian Press, October 21 — German testing, inspection, and certification organization TÜV SÜD and Accenture announced that they are using NVIDIA technology to accelerate the independent certification process for industrial automation and are showcasing the "physical AI safety suite" concept. The solution uses digital twins, AI agents, and simulation technology to conduct layered assessments of factory and warehouse layouts, robot fleet operations, and the safety of individual robot operations. TÜV SÜD expects that the digital process could enable production facilities to start operation up to 30% earlier, while it remains responsible for independent assessment and certification.

→
Flash 2026-10-21 19:33:15 · Bijing Flash

CrowdStrike and Nvidia expand AI security partnership

CrowdStrike and NVIDIA expand their collaboration in AI agent security, extending protection from the software layer to the chip layer.

→
⚠️ Information is for reference only. Data from public sources, may have delays.